Genisphere Licenses 3DNA Dendrimer Signal Amplification Technology to Chembio for Lateral Flow Rapid Test Applications Business Wire HATFIELD, Pa. -- July 29, 2013 Genisphere LLC has licensed its 3DNA® Signal Amplification technology to Chembio Diagnostics, Inc., a leader in point-of-care ("POC") diagnostic tests for infectious diseases. Chembio plans to use the signal enhancing technology for its Dual Path Platform (“DPP®”) rapid diagnostic pipeline tests, with the goal of achieving detection limits unique to rapid immunoassays thereby broadening potential applications of its technology by combining it with the Genisphere technology. “Sensitivity, specificity and reproducibility are important features for all diagnostic tests,” said Lawrence Siebert, Chembio's chief executive officer. “We believe Genisphere’s technology can further enhance the performance of our DPP® based assays leading to commercial success in this competitive marketplace." Genisphere’s 3DNA® Dendrimer technology has been used to improve the performance of a variety of assay platforms for protein and nucleic acid detection, including microarrays, ELISAs, bead-based flow cytometry, and most recently, lateral flow assays. The 3DNA® Dendrimer technology provides up to 100-fold improvement in sensitivity without increasing the assay’s complexity. This improved performance enables point-of-care analyses that have not previously been possible with conventional systems. The agreement between the two companies comes after a feasibility study in which Genisphere demonstrated the 3DNA® Dendrimer can be adapted to Chembio's Dual Path Platform. Such a close working relationship is a crucial part of Genisphere’s approach. “Genisphere’s business strategy is to partner with a few key successful players in growing markets,” said Jim Kadushin, Genisphere’s chief operations officer, “We believe Chembio is poised to continue its growth via the combination of our technology with their assay and reagent development activities.” Genisphere and Chembio will be presenting their respective products and technologies at this year’s AACC meeting, to be held July 29 - Aug 2 in Houston Texas. About Genisphere Genisphere LLC is a biotechnology company providing innovative tools for targeted drug delivery, clinical diagnostics and life science research based on the company’s 3DNA nanoparticle platform. Genisphere's unique, IP-protected, 3DNA dendrimer technology has broad applicability to improve the sensitivity in immunoassay and nucleic acid detection platforms, as well as to deliver therapeutics in a highly specific manner. Genisphere has successfully out-licensed several reagent kits to the research market, and provides dendrimers customized to improve the limit of detection of high-sensitivity lateral flow point-of-care tests, enabling their commercialization. Genisphere's diagnostic partners have a competitive advantage due to 3DNA’s ability to improve their test’s sensitivity, with minimal additional costs and no alterations to end user protocols. For targeted therapeutics, Genisphere provides the only customizable all-DNA drug delivery platform. Genisphere's robust nanocarrier delivers small drug, RNAi and gene construct therapeutics with greatly improved efficacy and reduced toxicity. The company is continuing to seek partnerships with biotechnology and pharmaceutical companies that could benefit from Genisphere's platform technology. For more information, please visit www.genisphere.com About Chembio Diagnostics Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For more information, please visit: http://www.chembio.com Contact: Genisphere Jim Kadushin 215-996-3027 Jim_Kadushin@genisphere.com Chempetitive Group Ken Li 312-997-2436 x 109 email@example.com
Genisphere Licenses 3DNA Dendrimer Signal Amplification Technology to Chembio for Lateral Flow Rapid Test Applications
Press spacebar to pause and continue. Press esc to stop.